Comparative effectiveness of the biosimilar CT-P13
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Yoo, Dae Hyun | - |
dc.date.accessioned | 2021-07-30T05:18:02Z | - |
dc.date.available | 2021-07-30T05:18:02Z | - |
dc.date.created | 2021-05-12 | - |
dc.date.issued | 2017-11 | - |
dc.identifier.issn | 2042-6305 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/4014 | - |
dc.description.abstract | The first biosimilar infliximab, CT-P13 (infliximab-dyyb) has been used for the treatment of inflammatory diseases for 4 years. CT-P13 has highly similar efficacy and safety profiles with a lower price than the originator infliximab and has been approved in 81 countries. Despite approval for clinical use, some knowledge gaps still limit the widespread and pertinent use of biosimilar CT-P13. One of the most important factors for proper utilization of CT-P13 for the treatment of immune-mediated inflammatory diseases is confidence in CT-P13, which could be enhanced by scientific evidence supporting the biosimilarity of CT-P13. Overall, five randomized controlled studies have been performed. For the other extrapolated indications, many observational induction and switching studies also support the utility of CT-P13 in the treatment of inflammatory diseases. Here, we review profiles of CT-P13 including physicochemical properties, clinical efficacy and safety data in all indications and current status. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | FUTURE MEDICINE LTD | - |
dc.title | Comparative effectiveness of the biosimilar CT-P13 | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Yoo, Dae Hyun | - |
dc.identifier.doi | 10.2217/cer-2017-0033 | - |
dc.identifier.scopusid | 2-s2.0-85035321893 | - |
dc.identifier.wosid | 000417036500006 | - |
dc.identifier.bibliographicCitation | JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH, v.6, no.8, pp.693 - 712 | - |
dc.relation.isPartOf | JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH | - |
dc.citation.title | JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH | - |
dc.citation.volume | 6 | - |
dc.citation.number | 8 | - |
dc.citation.startPage | 693 | - |
dc.citation.endPage | 712 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.isOpenAccess | N | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Health Care Sciences & Services | - |
dc.relation.journalWebOfScienceCategory | Health Care Sciences & Services | - |
dc.subject.keywordPlus | INFLAMMATORY-BOWEL-DISEASE | - |
dc.subject.keywordPlus | INFLIXIMAB CT-P13 | - |
dc.subject.keywordPlus | RHEUMATOID-ARTHRITIS | - |
dc.subject.keywordPlus | CROHNS-DISEASE | - |
dc.subject.keywordPlus | DOUBLE-BLIND | - |
dc.subject.keywordPlus | INNOVATOR INFLIXIMAB | - |
dc.subject.keywordPlus | ORIGINATOR INFLIXIMAB | - |
dc.subject.keywordPlus | CLINICAL-EXPERIENCE | - |
dc.subject.keywordPlus | PEDIATRIC-PATIENTS | - |
dc.subject.keywordPlus | NONMEDICAL SWITCH | - |
dc.subject.keywordAuthor | ankylosing spondylitis | - |
dc.subject.keywordAuthor | biosimilar | - |
dc.subject.keywordAuthor | CT-P13 | - |
dc.subject.keywordAuthor | immunogenicity | - |
dc.subject.keywordAuthor | inflammatory bowel disease | - |
dc.subject.keywordAuthor | infliximab | - |
dc.subject.keywordAuthor | rheumatoid arthritis | - |
dc.subject.keywordAuthor | treatment | - |
dc.identifier.url | https://becarispublishing.com/doi/10.2217/cer-2017-0033 | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
222, Wangsimni-ro, Seongdong-gu, Seoul, 04763, Korea+82-2-2220-1365
COPYRIGHT © 2021 HANYANG UNIVERSITY.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.